Phacilitate Leaders Forum

2018 Conference Agenda

2018 Conference Agenda

DAY 1
day1
DAY 2
day2

Loading
  1. Registration for Phacilitate Leaders Europe 2018 opens
  1. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  2. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  3. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  4. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  5. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  6. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  1. Morning coffee
  1. Manufacturing Scalability - Cell & Gene Therapy Europe

    Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

  2. Manufacturing Scalability - Cell & Gene Therapy Europe

    Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

  3. Manufacturing Scalability - Cell & Gene Therapy Europe

    Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

  4. Manufacturing Scalability - Cell & Gene Therapy Europe

    Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

  5. Manufacturing Scalability - Cell & Gene Therapy Europe

    Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

  6. Manufacturing Scalability - Cell & Gene Therapy Europe

    Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

  7. Manufacturing Scalability - Cell & Gene Therapy Europe

    Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

  1. Getting technical - Cell & Gene Therapy Europe

    A deep dive into process control: how can we increase quality through a comprehensive process control strategy?

  2. Getting technical - Cell & Gene Therapy Europe

    A deep dive into process control: how can we increase quality through a comprehensive process control strategy?

  3. Getting technical - Cell & Gene Therapy Europe

    A deep dive into process control: how can we increase quality through a comprehensive process control strategy?

  4. Getting technical - Cell & Gene Therapy Europe

    A deep dive into process control: how can we increase quality through a comprehensive process control strategy?

  5. Getting technical - Cell & Gene Therapy Europe

    A deep dive into process control: how can we increase quality through a comprehensive process control strategy?

  1. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part One

  2. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part One

  3. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part One

  4. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success

  5. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success

  6. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success

  7. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success

  8. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success

  1. Shared workshops

    Collaboration strategies: constructing a successful partnership with European clinical centres of excellence

  2. Shared workshops

    Collaboration strategies: constructing a successful partnership with European clinical centres of excellence

  3. Shared workshops

    Collaboration strategies: constructing a successful partnership with European clinical centres of excellence

  4. Shared workshops

    Collaboration strategies: constructing a successful partnership with European clinical centres of excellence

  1. Buffet lunch and lunch workshop
  1. Getting technical - Cell & Gene Therapy Europe

    Optimising vector production platforms to meet future ATMP industry success

  2. Getting technical - Cell & Gene Therapy Europe

    Optimising vector production platforms to meet future ATMP industry success

  3. Getting technical - Cell & Gene Therapy Europe

    Optimising vector production platforms to meet future ATMP industry success

  4. Getting technical - Cell & Gene Therapy Europe

    Optimising vector production platforms to meet future ATMP industry success: viral and non-viral vectors under the microscope

  5. Getting technical - Cell & Gene Therapy Europe

    Optimising vector production platforms to meet future ATMP industry success: viral and non-viral vectors under the microscope

  6. Getting technical - Cell & Gene Therapy Europe

    Optimising vector production platforms to meet future ATMP industry success: viral and non-viral vectors under the microscope

  7. Getting technical - Cell & Gene Therapy Europe

    Optimising vector production platforms to meet future ATMP industry success

  1. Immuno-Oncology Frontiers Europe

    Better together? Trends in combination partnering

  2. Immuno-Oncology Frontiers Europe

    Better together? Trends in combination partnering

  3. Immuno-Oncology Frontiers Europe

    Better together? Trends in combination partnering

  4. Immuno-Oncology Frontiers Europe

    Better together? Trends in combination partnering

  5. Immuno-Oncology Frontiers Europe

    Better together? Trends in combination partnering

  1. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part Two

  2. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part Two

  3. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part Two

  4. Investment for Advanced Therapies

    Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part Two

  5. Investment for Advanced Therapies

    Oncolytic viruses: what is on the horizon for this emerging immuno-oncology treatment?

  6. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part Two

  7. Investment for Advanced Therapies

    Oncolytic viruses: what is on the horizon for this emerging immuno-oncology treatment?

  1. Afternoon break
  1. Manufacturing Scalability - Cell & Gene Therapy Europe

    Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

  2. Manufacturing Scalability - Cell & Gene Therapy Europe

    Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

  3. Manufacturing Scalability - Cell & Gene Therapy Europe

    Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

  4. Manufacturing Scalability - Cell & Gene Therapy Europe

    Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

  5. Manufacturing Scalability - Cell & Gene Therapy Europe

    Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

  6. Manufacturing Scalability - Cell & Gene Therapy Europe

    Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

  7. Manufacturing Scalability - Cell & Gene Therapy Europe

    Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

  1. Getting technical - Cell & Gene Therapy Europe

    Gene therapy in the clinic : overcoming the in vivo clinical hurdles to ensure safe delivery to the patient and life time success of the vector

  2. Getting technical - Cell & Gene Therapy Europe

    Gene therapy in the clinic : overcoming the in vivo clinical hurdles to ensure safe delivery to the patient and life time success of the vector

  3. Getting technical - Cell & Gene Therapy Europe

    Gene therapy in the clinic : overcoming the in vivo clinical hurdles to ensure safe delivery to the patient and life time success of the vector

  4. Getting technical - Cell & Gene Therapy Europe

    Gene therapy in the clinic : overcoming the in vivo clinical hurdles to ensure safe delivery to the patient and life time success of the vector

  5. Getting technical - Cell & Gene Therapy Europe

    Gene therapy in the clinic : overcoming the in vivo clinical hurdles to ensure safe delivery to the patient and life time success of the vector

  1. Shared workshops

    Feedback loop: how are ATMP companies implementing the new GMP guidelines in Europe

  2. Shared workshops

    Feedback loop: how are ATMP companies implementing the new GMP guidelines in Europe

  3. Shared workshops

    Feedback loop: how are ATMP companies implementing the new GMP guidelines in Europe

  4. Shared workshops

    Feedback loop: how are ATMP companies implementing the new GMP guidelines in Europe

  1. Close of day 1 and networking drinks
  1. Registration opens
  1. Morning coffee
  1. Manufacturing Scalability - Cell & Gene Therapy Europe

    Planning for a successful supply chain strategy to harness globalisation and commercialisation for ATMPs

  2. Manufacturing Scalability - Cell & Gene Therapy Europe

    Planning for a successful supply chain strategy to harness globalisation and commercialisation for ATMPs

  1. Immuno-Oncology Frontiers Europe

    Accurately predicting patient response

  2. Immuno-Oncology Frontiers Europe

    Accurately predicting patient response

  3. Immuno-Oncology Frontiers Europe

    Accurately predicting patient response

  4. Immuno-Oncology Frontiers Europe

    Accurately predicting patient response

  5. Immuno-Oncology Frontiers Europe

    Accurately predicting patient response

  1. Investment for Advanced Therapies

    Next generation stem cell therapies: revived excitement in regenerative medicine

  2. Investment for Advanced Therapies

    Next generation stem cell therapies: revived excitement in regenerative medicine

  3. Investment for Advanced Therapies

    Next generation stem cell therapies: revived excitement in regenerative medicine

  4. Investment for Advanced Therapies

    Next generation stem cell therapies: revived excitement in regenerative medicine

  5. Investment for Advanced Therapies

    Next generation stem cell therapies: revived excitement in regenerative medicine

  6. Investment for Advanced Therapies

    Next generation stem cell therapies: revived excitement in regenerative medicine

  1. Buffet lunch
  1. Manufacturing Scalability - Cell & Gene Therapy Europe

    Utilizing the cutting edge of automation to drive robust, cost-effective cell-based therapy manufacturing at commercial scale

  2. Manufacturing Scalability - Cell & Gene Therapy Europe

    Utilizing the cutting edge of automation to drive robust, cost-effective cell-based therapy manufacturing at commercial scale

  3. Manufacturing Scalability - Cell & Gene Therapy Europe

    Utilizing the cutting edge of automation to drive robust, cost-effective cell-based therapy manufacturing at commercial scale

  4. Manufacturing Scalability - Cell & Gene Therapy Europe

    Utilizing the cutting edge of automation to drive robust, cost-effective cell-based therapy manufacturing at commercial scale

  5. Manufacturing Scalability - Cell & Gene Therapy Europe

    Utilizing the cutting edge of automation to drive robust, cost-effective cell-based therapy manufacturing at commercial scale

  1. Investment for Advanced Therapies

    Cancer vaccines: the next frontier in cancer treatments?

  2. Investment for Advanced Therapies

    Cancer vaccines: the next frontier in cancer treatments?

  3. Investment for Advanced Therapies

    Cancer vaccines: the next frontier in cancer treatments?

  4. Investment for Advanced Therapies

    Cancer vaccines: the next frontier in cancer treatments?

  5. Investment for Advanced Therapies

    Cancer vaccines: the next frontier in cancer treatments?

  6. Investment for Advanced Therapies

    Cancer vaccines: the next frontier in cancer treatments?

  1. Afternoon tea
  1. Manufacturing Scalability - Cell & Gene Therapy Europe

    The road to regulatory harmonisation for ATMP raw and starting material qualification, validation & selection on a European and global level

  2. Manufacturing Scalability - Cell & Gene Therapy Europe

    The road to regulatory harmonisation for ATMP raw and starting material qualification, validation & selection on a European and global level

  3. Manufacturing Scalability - Cell & Gene Therapy Europe

    The road to regulatory harmonisation for ATMP raw and starting material qualification, validation & selection on a European and global level

  4. Manufacturing Scalability - Cell & Gene Therapy Europe

    The road to regulatory harmonisation for ATMP raw and starting material qualification, validation & selection on a European and global level

  5. Manufacturing Scalability - Cell & Gene Therapy Europe

    The road to regulatory harmonisation for ATMP raw and starting material qualification, validation & selection on a European and global level

  1. Investment for Advanced Therapies

    Oncolytic viruses: what is on the horizon for this emerging immuno-oncology treatment?



 

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd